Abstract 2137P
Background
Performance ECOG status and staging are described as prognostic factors in oncologic outpatients while nutritional assessment can impact survival in both outpatients and inpatients. The aim of this study was to describe the Charslon Comorbidity Index (CCI), the nutritional status, the impact of opioid therapy and psycho-oncology and palliative care unit intervention for hospitalized cancer patients (pts).
Methods
A prospective multicentric study of pts hospitalized between January 2020 February 2022 at Vall d’Hebron and Sant Pau Hospitals [Plantology database] in Spain. Demographic and clinical variables such as CCI, laboratory results and nutritional status were collected at admission. Prognostic Nutritional Index (PNI) was calculated at admission. Quality of life (QoL) was collected through the EORTC-QLQ30 v.3 questionnaire. Statistical analysis was performed with SPSS v.29 (Log rank, Chi-square, Student’s t-test were used).
Results
A total of 1.431 patients (median age 66 years, 53.2% males) were included with a median of 9 days hospitalized. With a follow-up of 15 months, the median survival was 4.67 months after admission. Most pts (91.6%) had severe comorbidity (CCI ≥ 5 points) related to a lower survival (4.5 vs 12.8 months, p<0.001). A positive chair stand test for sarcopenia (12.2%) was associated with reduced survival (3.5 vs 9.1 months, p<0.001). Pts with hypoalbuminemia (65.3%) presented lower survival (3.5 vs 8.4 months, p<0.001). In addition, the PNI stratified 59.5% pts with serious malnutrition (PNI <40) linked to reduced survival (3.6 vs 7.9 months, p<0.001). Regarding supportive care, pts under opioid therapy (39.6%) had a higher QoL (mean EORTC QLQ-30 score of 73.4 vs 64.3, p<0.001). Palliative care team assessment and psycho-oncology intervention positively impacted in pts QoL (EORTC QLQ-30 of 74 vs 67.3, p<0.001, and 74.3 vs 65.2, p<0.001, respectively).
Conclusions
In hospitalized cancer pts, severe comorbidity, malnutrition and sarcopenia were associated with a reduced survival. Opioid therapy and psycho-oncological and palliative care unit intervention had a positive impact on the QoL of pts. Early supportive care interventions are key to improve symptomatology and preserve QoL of hospitalized cancer pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07